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Abstract
Cancer cells evolve through random somatic mutations. "Beneficial" mutations which disrupt key
pathways (e.g. cell cycle regulation) are subject to natural selection. Multiple mutations may lead to
the same "beneficial" effect, in which case there is no selective advantage to having more than one
of these mutations. Hence we are interested in finding sets of genes whose mutations are approx-
imately mutually exclusive (anti-co-occurring) within the TCGA Pancancer dataset. In principle,
finding the best set is NP Hard. Nevertheless, we will show how a new Mutation anti-co-OCcurrence
Algorithm (MOCA) provides an effective greedy search and testing algorithm with guaranteed con-
trol of the familywise error rate or false discovery rate, by combining some under-appreciated ideas
from frequentist hypothesis testing. These ideas include: (a) A novel exact conditional test for the
tendency of multiple sets to have a large/small union/intersection, which generalises Fisher’s exact
test of 2x2 tables. (b) Randomised hypothesis tests for discrete distributions. (c) Stouffer’s method
for combining p-values. (d) Weighted multiple hypothesis testing. A new approach to setting a-
priori weights which generates additional implicit hypothesis tests is suggested, and allows us to
preserve almost all statistical power when testing pairs despite introducing a combinatorially large
number of additional hypotheses.
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1. Introduction
Modern sequencing technology provides a wealth of genetic, genomic and metabolomic
data, and using this data to help map out the complex interactions between genes, and be-
tween genes and cancer progression is an ongoing effort. This paper describes an algorithm
for this based on detecting exclusivity patterns between somatic mutations.
It is widely believed that cancer progression is linked to the gradual accumulation of
somatic mutations in tumour cells, and in particular of mutations which disrupt the func-
tioning of certain key pathways such as cell cycle regulation and DNA repair (Hanahan
and Weinberg, 2011). These pathway-disrupting mutations allow the cells which acquire
them to multiply faster, thus conferring a selective advantage relative to the surrounding
cells, and hence these mutations will be more common in the population of cancer cells
than what the background mutation rate on its own would predict. Passenger mutations
which do not affect cancer progression will on the other hand occur only at the background
rate. This underlies analyses such as Kandoth et al. (2013) which identify genes relevant to
cancer through their individual somatic mutation rates
The functioning of each pathway is complex, involving a large number of genes, some
of which perform gene regulation functions. Hence each pathway may be disrupted by dif-
ferent somatic mutations in different patients. Although the first mutation to disrupt a given
pathway offers a selective advantage, we expect that the accumulation of additional muta-
tions in that pathway will typically not. Hence cancer cells in which multiple mutations
disrupt one pathway will be rarer than if such mutations were statistically independent. In
an idealised scenario, one would expect that the set of somatic mutations in each patient
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will consist of exactly one mutation disrupting each of the pathways. Across patients, the
mutations affecting a given pathway would then be perfectly mutually exclusive.
Reality is of course more complex than the simplified description given above. For
example certain mutations may disrupt multiple pathways (e.g. TP53), and certain pairs of
mutation exhibit synthetic lethality (McCarthy, 2011; Li et al., 2014). Because of various
reasons including background mutation rates, possible residual selective advantages in hav-
ing more than one mutation per pathway, sequencing errors, and the existence of additional
pathway disruption mechanisms, some patients may have multiple mutations from genes
in a given pathway, and some may have none. A tendency for mutations in some of the
genes affecting a given pathway to co-occur less than one would expect by chance never-
theless will remain, and can be detected using statistical techniques. Various analyses and
interpretations of both co-occurrence and anti-co-occurrence patterns in somatic mutations
have been suggested, mostly based on testing pairs of genes (Yeang et al., 2008; Cui, 2010;
Gu et al., 2013; Wang et al., 2011; Gu et al., 2010). In this paper we are interested only in
detecting anti-co-occurrence, i.e. appproximate mutual exclusivity between genes, and we
wish to consider not just pairs but also larger sets of genes.
Multiple methods have been suggested to search for sets of anti-co-occurring genes
(Leiserson et al., 2015, 2013; Vandin et al., 2012; Babur et al., 2015; Constantinescu et al.,
2015). The Dendrix algorithm of Vandin et al. (2012) showed that once the tendency of
driver mutations to belong to mutually exclusive sets is taken into account, even relatively
rare driver mutations can be identified ‘de novo’ from somatic mutation data, i.e. with-
out any prior pathway information. Dendrix searches for sets of genes with high overall
coverage and low overlap. This approach has been further developed in the Multi-Dendrix
algorithm (Leiserson et al., 2013) which finds multiple gene sets simultaneously and the
group’s current state of the art CoMEt (formerly Dendrix++) (Leiserson et al., 2015) which
uses a statistical test of exclusivity to score sets. See Babur et al. (2015) for a review and
comparison of methods.
In Section 2 we introduce some basic notation. Section 3 describes how we compute
the statistical significance of the anti-co-occurrence of a set of genes/alterations by gen-
eralising Fisher’s exact test from pairs of alterations to sets of alterations, and applying a
randomised Stouffer’s method to combine information from multiple tumour types. Sec-
tion 4 introduces a novel a weighted Bonferroni correction scheme to control the family-
wise error rate whilst maintaining high power for small sets. Section 5 describes a greedy
algorithm to generate a shortlist of candidate gene sets which will be tested according to
Section 3. Finally Section 6 shows the pattern of anti-co-occurrence detected by our method
on a combined dataset of 5807 tumour samples from 22 tumour types. R code implement-
ing our method and the full list of 654 statistically significant gene sets are available at
https://github.com/PaulGinzberg/MOCA/.
2. Setup and Notation
For each patient in the data we identify for each gene the presence or absence of three
possible alterations: whether there are any functional SNVs (single nucleotide variations)
or CNVs (copy number variations), which may be AMPs (amplifications) or DELs (dele-
tions). This produces an m × n binary matrix A = (aij) where each patient or sample
corresponds to a column, and each gene corresponds to (up to) three rows, one for each
of the three types of alterations considered (SNV, AMP, DEL). Hence aij = 1 means “al-
teration i is present/mutated in sample j”. For the purpose of understanding the statistical
methods, one may conflate genes with alterations, i.e. assume that each row in A corre-
sponds to a different gene. After pre-processing, which is detailed in Section 6.1, our data
contains m = 1418 alterations and a total of n = 5807 samples. These 5807 samples are
split across 22 different types of cancer, as described in Table 2.
For ease of comparison, we will follow a notation similar to Leiserson et al. (2013).
M ⊆ {1, . . . ,m} will denote a set of alterations of size |M |. The coverage Γ(i) of alter-
ation i is the number of samples for which this alteration is present Γ(i) = |{j : aij = 1}| =∑n
j=1 aij . Let C = (Γ(1), . . . ,Γ(m)) denote the vector of these marginal coverages. Al-
teration set M is considered to be present/mutated in sample j if at least one of the alter-
ations from M is present in sample j. Hence the coverage of M is defined as
Γ(M) =
∣∣∣∣∣∣
j : ∑
g∈M
agj ≥ 1

∣∣∣∣∣∣ . (1)
M is perfectly mutually exclusive iff no sample has more than one alteration from M ,
i.e. iff Γ(M) =
∑
g∈M Γ(g). The overlap of an alteration setM is the number of additional
mutations compared to the perfect mutual exclusivity case ω(M) =
∑
g∈M Γ(g)− Γ(M).
3. Testing for group-wise anti-co-occurrence
3.1 An exact test for whether the intersection/union of multiple sets is smaller/larger
than expected by chance
Given an alteration set M = {g1, . . . , g|M |} we wish to test the following hypotheses:
H0 : The alterations ag1j , . . . , ag|M|j occur independently.
H1 : The alterations ag1j , . . . , ag|M|j tend to co-occur less frequently than if they were
independent, i.e. for i, ` ∈M P(aij = 1 ∩ a`j = 1) < P(aij = 1) P(a`j = 1).
When |M | = 2 the most commonly used test for this problem is a one-sided Fisher’s
exact test for the 2 × 2 contingency table of the events ag1j = 1 and ag2j = 1. The test
rejectsH0 for large values of the test statistic Γ(M). The exact conditional null distribution
of Γ(M)− Γ(g1) given (Γ(g1),Γ(g2)) (or equivalently given C) is Hypergeometric:
Γ(M) | (Γ(g1),Γ(g2)) ∼ Γ(g1) + Hypergeom(n, n− Γ(g1),Γ(g2)), (2)
where the hypergeometric distribution has probability mass function
fHypergeom(n,k,r)(x) =
(
k
x
)(
n−k
r−x
)(
n
r
) ,
over the support max(0, k + r − n) ≤ x ≤ min(k, r).
Let us now consider the case of groupwise testing, i.e. |M | > 2. One approach which
has been suggested in the literature is do define fully parametric generative models of the
mutations under both the null and alternative hypothesis and then perform an asymptotic
likelihood ratio test (Szczurek and Beerenwinkel, 2014; Constantinescu et al., 2015). This
approach relies on the validity of the underlying generative models. We will instead gen-
eralise Fisher’s exact test by deriving the conditional null distribution of Γ(M) given C.
The use of the test statistic Γ(M) for |M | ≥ 2 had already been suggested by Ciriello et al.
(2012). However they relied on Monte Carlo permutation testing to compute p-values, an
approach which is computationally prohibitive when the p-values are very small. We will
provide an algorithm for fast computation of exact p-values for the test statistic Γ(M).
Assume H0. We will now derive the conditional null distribution of Γ(M) given
Γ(g1), . . . ,Γ(g|M |), (or equivalently given C) by iterated convolution. For s = 1, . . . , |M |
let M (s) = {g1, . . . , gs} ⊆M , so that M (|M |) = M . If 1 < s ≤ |M | then
Γ(M (s)) | (Γ(M (s−1)),Γ(gs)) ∼ Γ(M (s−1)) + Hypergeom(n, n− Γ(M (s−1)),Γ(gs)).
(3)
Using (3) and the fact that under H0 Γ(M (s)) is conditionally independent of C given
(Γ(M (s−1)),Γ(gs)), we can compute the conditional probability mass function fΓ(M)|C(x)
iteratively as
fΓ(M(s))|C(x) =
∑
y
fHypergeom(n,n−y,Γ(gs))(x− y)fΓ(M(s−1))|C(y). (4)
The p-value for our test is then
pM =
∑
x≥Γ(M)
fΓ(M(|M|))|C(x). (5)
Note that computing this p-value only requires evaluating the probability mass function
for values of x in the right tail at each iteration. In particular, if M is perfectly mutually
exclusive then each sum (5), (4) contains only one term.
Because our test is based on Γ(M), it has a simple and intuitive interpretation: “Given
|M | subsets of {1, . . . , n} of sizes Γ(g1), . . . ,Γ(g|M |), is the size Γ(M) of their union
larger than would be expected for independently drawn random subsets of those sizes?”. If
we wished to detect co-occurrence rather than anti-co-occurrence could also perform the
opposite one-sided test and reject for small values of Γ(M). Also, because n−Γ(M) is the
size of the intersection of |M | subsets of {1, . . . , n} of sizes n − Γ(g1), . . . , n − Γ(g|M |),
we can apply our test to intersections instead of unions. We expect that our generalisation
of Fisher’s exact test will have applications beyond biostatistics.
Because it requires |M | − 2 “convolutions” (plus two sums), the computational com-
plexity of our iterative approach is linear in |M |. Leiserson et al. (2015) perform exact
groupwise testing but uses as a test statistic the number of samples for which exactly one
alteration from M is present T (M) =
∣∣∣{j : ∑g∈M agj = 1}∣∣∣. For |M | = 2 both tests
are equivalent and reduce to Fisher’s exact test. The two tests are also equivalent when
there is perfect mutual exclusivity. For |M | > 2 and imperfect mutual exclusivity how-
ever the computational complexity of the enumeration technique employed by Leiserson
et al. (2015) grows exponentially with |M |, and becomes impractical for large sample sizes
except in the extreme tail of the distribution. In practice the two tests will tend to give
similar answers, although the statistic T (M) has the advantage of being more robust to the
presence of hypermutated phenotypes.
Suppose for example that g1, g2 ∈M are respectively amplification and deletion of the
same gene. Then it does not make sense to treat the anti-co-occurrence between g1 and g2
as evidence of any interesting biological relationship, since the two alterations are perfectly
mutually exclusive by definition. Hence, whenever multiple alterations of a given gene are
present in an alteration set, we will condition on the total coverage of these multiple alter-
ations, and not just the coverage of each alteration. This is equivalent to treating {g1, g2}
as a single alteration of size Γ({g1, g2}) in our test.1
1The only difference is that when performing our multiple hypothesis testing correction, the set size will be
the original the number of alterations, not the number of genes.
3.2 Combining p-values across cancer types
The mutation frequencies of certain genes is different in different cancer types, and indeed
some mutations may be specific to only one type or subtype of cancer. In a dataset with
multiple cancer types, this effect can on its own induce anti-co-occurrence between func-
tionally unrelated alterations simply because the cancer types in which they are common
are different. To avoid this effect, when applying our method we will compute p-values
on each cancer type separately, and then combine these p-values with Stouffer’s method.
Two issues must however be addressed. First, what weights to use in Stouffer’s method,
and second how to handle effects caused by the fact that the distribution of our test statistic
Γ(M) (and hence of our p-values) is discrete.
Stouffer’s method consists in computing the combined p-value
pStouffer = Φ
(∑
τ vτΦ
−1(pτ )√∑
τ v
2
τ
)
,
where Φ is the standard normal CDF, vτ are (unnormalised) weights, and pτ are the p-values
from the independent tests being combined.
The asymptotically optimal weights to use in the case where |M | = 2 (and the effect
size is the same for all τ ) are well known, and are the inverse asymptotic standard deviation
of the empirical log-odds ratio (which is a variance-stabilised parameter estimator) under
the null. The (unnormalised) weight for each tumour type τ in this case is
v{g1,g2},τ =
(
nτ
Γτ (g1) Γτ (g2)
+
nτ
Γτ (g1)(n− Γτ (g2))
+
nτ
(n− Γτ (g1)) Γτ (g2) +
nτ
(n− Γτ (g1))(n− Γτ (g2))
)− 1
2
,
where nτ is the number of samples with tumour type τ and the coverages Γτ are computed
using only those samples with tumour type τ .
Finding a nice closed-form formula for the more general case |M | > 2 is non-trivial
since it requires us to formulate some appropriate parametric alternative distribution gen-
eralising the non-central hypergeometric distribution, and we opt instead for the following
heuristic weight vM , based on assuming that the power of the groupwise test can be ap-
proximated as the power of combining all pairwise tests between genes in the group, as
though they were independent:
vM,τ =
|M |−1∑
k=1
|M |∑
`=k+1
v2{gk,g`},τ
 12 .
The fact that these weights are based on approximate power does not make our testing
procedure approximate, although it may cause the overall power of our combined test to be
lower than it would be with optimal choices of weights. Although for each M our weights
depend on the data, they are valid because they only use information in C, and the tests
being performed are all conditional on fixed C.
In the case of exact tests based on continuous test statistics, the null distribution of each
pτ will be Uniform(0, 1), and so will the null distribution of pStouffer. This is no longer
true with discrete tests. If we apply Stouffer’s method naively, then we will optain a p-
value satisfying P(pStouffer ≤ α) ≤ α, but it may be catastrophically conservative. Indeed,
if even just one of the tests being combined returns a p-value of 1, then the overall p-value
is 1.
Kincaid (1962) considers various approaches for solving this problem when Fisher’s
method for combining p-values is used. However, their remarks are also valid for Stouf-
fer’s method. One of the simpler suggested approaches is a simplified version of Lan-
caster’s procedure, which is equivalent to using mid-p-values pmidτ = pτ − 0.5(pτ − p−τ ),
where p−τ = P0(Γ(M) > γ(M)), instead of p-values pτ = P0(Γ(M) ≥ γ(M)). The
logic behind this is that the distribution of the mid-p-value is better approximated by the
uniform distribution than that of the p-value. Because of its simplicity we will use this
approximate approach to combine p-values from Fisher’s exact test used internally in our
greedy algorithm for generating candidate gene sets (See Section 5). However, because this
approximate approach does not guarantee P(pStouffer ≤ α) ≤ α, (and does not produce a
mid-p-value) we will use instead the Pearson approach (Kincaid, 1962) for combining the
final p-values: This latter approach consists in using independently randomised p-values
prandτ = pτ − (pτ − p−τ ) ·Uniform(0, 1)
instead of the original p-values pτ . Combining randomised p-values will never increases
the number of false negatives compared to naively combining non-randomised p-values, but
still controls the false positive rate so that P(pStouffer ≤ α) = α. For large sample sizes,
(and finite log-odds-ratio) this randomised pStouffer is restricted to lie in a small interval
below the best (but computationally prohibitive) non-randomised p-value, so the variability
introduced by randomisation becomes negligible.
4. A novel weighted multiple hypothesis testing scheme
It is appropriate to correct the alteration set p-values for multiple hypothesis testing. Be-
cause the procedure for generating candidate alteration sets described in Section 5 uses
information from the data (other than C), the multiple hypothess testing correction must
also take into account all tests which could have been performed, even when the number
of candidate alteration sets actually tested is limited. The total number of alteration sets
which could have been tested is
∑kmax
k=2
(
m
k
)
, where kmax denotes the maximum allowed al-
teration set size. If we apply a standard unweighted multiple hypothesis testing correction,
e.g. a Bonferroni correction, then the corrected p-values will depend strongly on the choice
of kmax. If we are agnostic a-priori about the size of alteration sets and use kmax = m,
then the number of alteration sets which could have been tested is 2m −m − 1 > 10426.
This is so large that there is little hope of any statistical significance after such a standard
unweighted multiple hypothesis testing correction.
Since the main motivation behind performing groupwise testing is that the groupwise
test can be much more powerful than pairwise tests, we must ensure that the loss of power
caused by introducing additional hypotheses with |M | > 2 does not overwhelm the gains.
We propose to use a weighted multiple hypothesis testing correction scheme which up-
weights smaller alteration sets at the expense of larger ones, and which is based on the
argument that the smallest p-values after weighting should typically correspond to the most
“interesting” alteration sets. In practice our proposed approach leads to only a small in-
crease in the multiple hypothesis correction applied to pM when |M | = 2, despite the large
number of additional hypotheses.
For simplicity, we will assume that there is a single cancer type in this section. Define
the conditional null probability measure P0 (•) = P (•|C, H∅) corresponding to the global
null hypothesis H∅ that the rows of A are independent. Then the p-value obtained when
applying our test to alteration set M is pM = P0 (Γ(M) ≥ γ(M)), where γ(M) is the
observed value of the test statistic Γ(M).
Let 0 < α ≤ 1 (which need not be equal to the significance level used for selecting
statistically significant alteration sets) and define the weights
wM =
(∑kmax
`=2
(
m
`
))∏|M |
k=2
(
1− (1− α) 1m−k+1
)
∑kmax
`=2
(
m
`
)∏`
k=2
(
1− (1− α) 1m−k+1
) , (6)
which are normalised to have an average value of 1.
Lemma 1.
P0
(
∃g /∈M : w−1M∪{g}pM∪{g} < w−1M pM
∣∣∣Γ(M)) ≤ α
Proof. Γ(M) is a random variable for each M , and let us first consider arbitrary fixed data
leading to an observed value γ(M).
pM∪{g} =
∑
k≥0
P0 (Γ(M ∪ {g}) ≥ γ(M ∪ {g})|Γ(M) = k) P0(Γ(M) = k)
≥
∑
k≥γ(M)
P0 (Γ(M ∪ {g}) ≥ γ(M ∪ {g})|Γ(M) = k) P0(Γ(M) = k)
≥ P0 (Γ(M ∪ {g}) ≥ γ(M ∪ {g})|Γ(M) = γ(M))
∑
k≥γ(M)
P0(Γ(M) = k)
= P0 (Γ(M ∪ {g}) ≥ γ(M ∪ {g})|Γ(M) = γ(M)) · pM
= pM∪{g}|M · pM ,
where pM∪{g}|M = P0 (Γ(M ∪ {g}) ≥ γ(M ∪ {g})|Γ(M) = γ(M)) denotes the p-value
obtained by a standard one-sided Fisher’s exact test of independence between the events
“having a mutation for alteration g” and “having at least one mutation amongst the alter-
ations in set M”.
Let us now treat the data, and hence pM∪{g} and pM∪{g}|M , as random variables. Note
that for any g /∈ M , |M ∪ {g}| = |M | + 1 and wM∪{g}wM = 1 − (1 − α)
1
m−|M| . Also note
that that because pM∪{g}|M is a p-value for fixed Γ(M), P0
(
pM∪{g}|M ≤ α
∣∣Γ(M)) ≤ α.
1− P0
(
∃g /∈M : w−1M∪{g}pM∪{g} < w−1M pM
∣∣∣Γ(M))
=
∏
g/∈M
P0
(
w−1M∪{g}pM∪{g} ≥ w−1M pM
∣∣∣Γ(M))
≥
∏
g/∈M
P0
(
pM∪{g}|M ≥
wM∪{g}
wM
∣∣∣∣Γ(M))
≥
∏
g/∈M
(
1− wM∪{g}
wM
)
= 1− α
The inequality pM∪{g} ≥ pM∪{g}|M · pM becomes an equality when M ∪ {g} has
perfect mutual exclusivity; and the null distribution of the discrete p-value pM∪{g}|M con-
verges to a Uniform(0, 1) for large sample sizes. Hence the inequalities in the proof of
Lemma 1 are “tight” for small α, and any weighting scheme with weights proportional to
kmax = 2 kmax = 3 kmax = 4 kmax ≥ 5
|M | = 2 1.004653 · 106 1.021830 · 106 1.022050 · 106 1.022053 · 106
|M | = 3 ∞ 2.820910 · 1010 2.821518 · 1010 2.821524 · 1010
|M | = 4 ∞ ∞ 7.783707 · 1014 7.783725 · 1014
|M | = 5 ∞ ∞ ∞ 2.145775 · 1019
Table 1: Values for the weighted Bonferroni Correction (7) where m = 1418 and α =
0.05. The case of unweighted pairwise tests is in bold.
wM · (1 + )|M |,  > 0 will in general no longer satisfy Lemma 1. In this sense, the weight-
ing scheme (1) is the flattest (the one least penalising large sets) which satisfies Lemma 1.
When using a weighting scheme which does not satisfy Lemma 1 for α = 0.5 (e.g. uni-
form weights), we run the risk that most of the highly significant aletration sets will contain
passenger mutations. Hence such weighting schemes arguably favour larger alteration sets
unfairly over smaller ones. In our analysis we will set α = 0.05.
We will use a weighted Bonferroni correction. Because the weights (6) are normalised
so that the average weight is 1 this controls the familywise error rate (Roeder and Wasser-
man, 2009, Lemma 2.1). The same weighting scheme could be used with a weighted
Benjamini-Hochberg procedure to control the false discovery rate (Genovese et al., 2006,
Theorem 1). The weighted Bonferroni correction consists in multiplying the uncorrected
p-value pM corresponding to an alteration set M by∑kmax
`=2
(
m
`
)
wM
=
∑kmax
`=2
(
m
`
)∏`
k=2
(
1− (1− α) 1m−k+1
)
∏|M |
k=2
(
1− (1− α) 1m−k+1
) . (7)
For small α, large m, and large kmax, (7) can be well approximated by
(eα − 1− α)α−|M ||M |!
(
m
|M |
)
.
It is clear from Table 1 that our weighted Bonferroni correction depends weakly on
kmax, and indeed when compared to the standard approach of only testing pairs of alter-
ations (kmax = 2), it causes only a small increase in the multiple hypothesis correction
applied to pairwise tests, even when setting kmax = m. The results in Section 6.2 show
that despite almost all of the weight being focused on the smallest sets (|M | = 2), in most
cases larger sets (3 ≤ |M | ≤ 6) still obtain smaller weighted p-values than any of the pairs
that they contain.
5. A greedy algorithm for generating candidate sets
Because even for moderate kmax the number of possible alteration sets to consider
∑kmax
k=2
(
m
k
)
is too large, we cannot exhaustively compute all pM , and must select a limited number of
candidate alteration sets to test. We set the maximum alteration set size to kmax = 10. The
number of alteration sets satisfying 2 ≤ |M | ≤ 10 is∑10k=2 (1418k ) ≈ 8.84 · 1024.
Constantinescu et al. (2015) generate candidate sets by considering the cliques in a
graph where the edges indicate statistically significant pairwise anti-co-occurrence. Leis-
erson et al. (2015) explores the space of possible sets of sets of alterations through an
MCMC algorithm which swaps out one alteration at a time. As a simpler alternative to
MCMC, Vandin et al. (2012) also considers a greedy approach to finding the alteration set
which maximises their test statistic W (M) = Γ(M) − ω(M), and show that for large
sample sizes the greedy approach succeeds with high probability.
The greedy algorithm for generating candidate alteration sets is based on two insights:
Firstly, each alteration can also be considered as an alteration set of size 1. Secondly,
Fisher’s exact test can be used to test for anti-co-occurrence between alteration sets, i.e.
(2) remains valid if M = g1 ∪ g2 where g1 and g2 are alteration sets rather than single
alterations. The proposed algorithm takes as inputs the binary alteration matrix A and the
number of alteration sets one wishes to generate maxIter (which we will set to 5000). It
then generates at each iteration a new alteration set by taking the union of the two existing
alteration sets which are the most significantly anti-co-occurring. Pairs of alteration sets
whose union is an existing alteration set or is larger than kmax are ignored. To ensure that
the space of small alteration sets is properly explored, the iterations are split into kmax − 1
equal-sized epochs and the maximum allowed size of new alteration sets is increased by 1
from 2 to kmax between epochs.
As described in Section 3.2, within this greedy algorithm significance is measured by
performing Fisher’s exact tests independently on each of the tumour types and combining
the mid p-values of these tests. An advantage of using mid-p-values over p-values here is
that the ordering of mid-p-values is more appropriate for our purposes: If g1 and g2 are
perfectly mutually exclusive, but their p-value is close to 1 because of discreteness, then
they are arguably more significantly anti-co-occurring than two alterations with a large
overlap. The mid-p-value of perfectly mutually exclusive alterations will always be ≤ 0.5.
The fact that the tests used in the greedy algorithm may be liberal is not an issue since the
purpose of this step is only to heuristically search for candidate alteration sets on which
accurate groupwise testing will be performed.
All subsets of the candidate alteration sets are then added to the set of candidate alter-
ation sets.
Finally, the exact p-value pτ for each candidate alteration set is computed for each tu-
mour type as described in Section 3.1, and these are randomised and combined as described
in Section 3.2 to produce an overall p-value pM = prandM . The Bonferroni correction (7)
with α = 0.05 is then applied, and Bonferroni-corrected p-values greater than α = 0.05
are discarded as non-significant. The ordering of Bonferroni-corrected p-values is the same
as the ordering of weighted p-values, and in light of Lemma 1 we also discard an alteration
set as non-significant if any of its subsets (or supersets) has a smaller Bonferroni-corrected
p-value.
6. Application to the TCGA Pancancer dataset
6.1 Pre-processing
Somatic SNP and CNV data is obtained for 22 tumour types as described in Table 2. All but
one of the tumour type datasets (and more than 99% of samples) was collected by TCGA.
The total sample size across all 22 datasets is n = 5807.
Selection of genes: Although the proposed algorithm can be used in theory to detect
genes which are relevant to cancer purely through their mutation pattern relative to other
genes, this will not be attempted in this paper, and we will focus instead only on the search
for relationships between genes. Hence we will restrict our analysis to genes which have
already been identified as potentially relevant to cancer because of their high mutation rate,
or through other means. Specifically, we include in our analysis the 127 genes which were
identified as significantly mutated in (Kandoth et al., 2013, Supplementary Table 4) and
the 487 genes listed by the Catalogue Of Somatic Mutations in Cancer (COSMIC) cancer
gene census (Futreal et al., 2004, Supplementary Table S1). Combining these two sources
Tumour Type Acronym Samples Publication
Acute myeloid leukemia AML 193 (TCGA, 2013b)
Urothelial bladder cancer BLCA 129 (TCGA, 2014b)
Breast cancer BRCA 975 (TCGA, 2012c)
Colon adenocarcinoma COAD 216 (TCGA, 2012b)
Glioblastoma multiforme GBM 281 (TCGA, 2008)
Head & neck squamous cell carcinoma HNSC 302 (TCGA, 2015a)
Clear cell kidney carcinoma KIRC 292 (TCGA, 2013a)
Papillary kidney carcinoma KIRP 161 (TCGA, 2016)
Lower grade glioma LGG 286 (TCGA, 2015b)
Liver hepatocellular carcinoma LIHC 187
Lung adenocarcinoma LUAD 466 (TCGA, 2014c)
Lung squamous cell carcinoma LUSC 178 (TCGA, 2012a)
Ovarian serous cystadenocarcinoma OV 139 (TCGA, 2011)
Pancreatic ductal adenocarcinoma PAAD 168
Prostate cancer (castration-resistant) CRPC 58 (Grasso et al., 2012)
Prostate adenocarcinoma PRAD 199 (TCGA, 2015d)
Rectal adenocarcinoma READ 81 (TCGA, 2012b)
Sarcoma SARC 257
Cutaneous melanoma SKCM 364 (TCGA, 2015c)
Stomach adenocarcinoma STAD 229 (TCGA, 2014a)
Papillary thyroid carcinoma THCA 403 (TCGA, 2014d)
Uterine corpus endometrial carcinoma UCEC 243 (TCGA, 2013c)
Table 2: Number of samples for each tumour type. All data is from The Cancer Genome
Atlas Research Network, with the exception of the additional prostate cancer dataset from
Grasso et al.
yields a whitelist of 547 genes. Because there are three possible alteration types (SNV,
AMP, DEL) for each gene, the whitelist corresponds to 1641 possible alterations.
Alterations which are mutated in exactly the same set of samples (i.e. identical rows in
A) are merged into one since in terms of their anti-co-occurrence they are mathematically
indistinguishable. This step can reduce the computational requirements and can also aid
interpretation. None of these merged alterations appear in the significant sets.
The number of alterations considered is reduced further by eliminating those alterations
which are too rare for there to be a realistic chance of measuring statistically significant
anti-co-occurrence after a Bonferroni correction is applied. The minimum number of muta-
tions required for inclusion is set to be greater than log2(Number of alterations remaining−
1). Based on this heuristic, all alterations with Γ(g) < 11 were removed. This leaves us
with a final binary mutation matrix A describing m = 1418 alterations across n = 5807
samples.
Missing values in A are set to 0 (i.e. the alteration is assumed to be absent).
6.2 Results
After a weighted Bonferroni correction with α = 0.05 as the significance level, We find
654 statistically significant sets of anti-co-occurring alterations (6 pairs, 147 triplets, 222
quadruplets, 261 quintuplets and 18 sextuplets). The 10 most statistically significant sets
are given in Table 3. These alteration sets contain a total of 125 different alterations (116
different genes). We can think of each alteration set as a fully connected graph with alter-
ations as vertices. The union of these 654 graphs contains 125 vertices and 969 edges. This
graph is displayed in Figure 1. The rarest alteration out of these 125 is TNFAIP3(D) with
35 mutations (0.6%).
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Figure 1: The graph obtained from the union of the 654 statistically significant (α = 0.05)
alteration sets obtained with our approach. The size of nodes is proportional to the coverage
of the alteration. The color of nodes indicates the two communities (detected by label
propagation).
The increased power from using groupwise testing is evident if we compare with the re-
sults from a pairwise analysis. If we compute pairwise p-values based on Fisher’s exact test
(combined over all cancer types),2 then after applying the Bonferroni correction m(m−1)2 ,
only 82 pairs of alterations are significant at the level α = 0.05, between 67 unique al-
terations (63 genes). The rarest alteration out of these 67 is TLX1(D) with 59 mutations
(1%). Only one of the pairs detected by the pairwise approach is missing an edge in the
graph obtained with the groupwise approach, namely (EIF4A2(A),PTEN), and this is be-
cause EIF4A2(A) is not in any of the sets detected by the groupwise approach. If we take
the graph union of these pairs, displayed in Figure 2, there are no cliques of size ≥ 3, i.e.
the pairwise approach fails to detect any groups of size ≥ 3. The graph does however split
into 7 connected components.
2In the pairwise analysis we used mid-p-values instead of randomised p-values in Stouffer’s method.
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Figure 2: The graph obtained from the statistically significant pairs (α = 0.05) of anti-co-
occurring alterations. The size of nodes is proportional to the coverage of the alteration.
The color of nodes is based on the connected components.
1
n Γ(M)
p-value
(uncorrected)
p-value
(Weighted
Bonferroni)
Alteration Set
1 25.6% 1.22 · 10−53 5.20 · 10−39 TOP1(A), BRAF, HRAS, KRAS, NRAS
2 24.0% 8.11 · 10−45 1.22 · 10−32 SDC4(A), BRAF, KRAS, NRAS
3 42.8% 3.77 · 10−27 1.61 · 10−17 ARID1A(D), PTEN, TP53
4 37.2% 2.04 · 10−26 8.70 · 10−17 STIL(D), HMGA2(A), TP53
5 9.2% 3.84 · 10−26 1.64 · 10−16 TLX1(D), RBM15(D), ATRX
6 36.3% 4.78 · 10−26 2.04 · 10−16 MUTYH(D), TNFAIP3(D), TP53
7 48.1% 5.73 · 10−31 2.45 · 10−16 STIL(D), TP53, MDM2(A), PTEN, CTCF(D)
8 36.8% 6.84 · 10−26 2.92 · 10−16 RBM15(D), TNFAIP3(D), TP53
9 13.9% 8.82 · 10−26 3.76 · 10−16 FAM46C(D), NCOA4(D), ATRX
10 45.3% 4.26 · 10−28 6.43 · 10−16 JUN(D), FANCA(D), TP53, PTEN
Table 3: The top 10 most significant alteration sets obtained with our method af-
ter Bonferroni correction. (A) indicates an amplification, (D) indicates a deletion.
The full list is available at https://github.com/PaulGinzberg/MOCA/blob/
master/example-output/pancancer-test2-significantv2.txt
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